This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

Prevalence of Metabolic Syndrome and Associated Factors in a Cohort of Individuals With Treatment-Resistant Depression: Results From the FACE-DR Study

Ophélia Godin, PhDa,b,†¡,*; Djamila Bennabi, MD, PhDa,c,†¡; Antoine Yrondi, MD, PhDa,d; Raphaelle Richieri, MD, PhDa,e; Thierry D†Amato, MD, PhDa,f; Franck Bellivier, MD, PhDa,g; Thierry Bougerol, MD, PhDa,h,i,j; Mathilde Horn, MD, PhDa,k; Vincent Camus, MD, PhDa,l; Philippe Courtet, MD, PhDa,m; Olivier Doumy, MD, PhDa,l; Jean Baptiste Genty, MD, PhDa,o,p,q; Wissam El-Hage, MD, PhDa,h; Frederic Haesebaert, MD, PhDa,f; Jerôme Holtzmann, MD, PhDa,h,i,j; Christophe Lancon, MD, PhDa,e; Marion Leboyer, MD, PhDa,o,p,q; Pierre Michel Llorca, MD, PhDa,r; Julia Maruani, MD, PhDa,g; Fanny Molière, MD, PhDa,i; Ludovic Samalin, MD, PhDa,r; Laurent Schmitt, MD, PhDa,d; Florian Stephan, MD, PhDa,r; Guillaume Vaiva, MD, PhDa,k; Michel Walter, MD, PhDa,s; Bruno Aouizerate, MD, PhDa,n; and Emmanuel Haffen, MD, PhDa,c; for the FondaMental Advanced Centers of Expertise in Resistant Depression (FACE-DR) Collaboratorst

Published: October 15, 2019

Article Abstract

Background: The aim of this study was to estimate the prevalence of metabolic syndrome (MetS) and its components in a cohort of French patients with treatment-resistant depression (TRD) and to determine correlations with sociodemographic, clinical, and treatment-related factors.

Methods: From 2012 to 2018, 205 patients who met DSM-IV criteria for major depressive episode with moderate-to-severe symptoms (Montgomery-Asberg Depression Rating Scale score ≥ 20), and at least Stage II resistance according to Thase and Rush criteria were enrolled in the FondaMental Advanced Centers of Expertise in Resistant Depression (FACE-DR) cohort. Data on sociodemographic and clinical characteristics, lifestyle information, and treatment and comorbidities were collected, and a blood sample was drawn. MetS was defined according to the criteria of the International Diabetes Federation.

Results: Overall, 38% of individuals with TRD met criteria for MetS. The frequency of MetS was significantly higher in men than in women only for patients aged 40 years or older (46.3% vs 35.2%, P = .0427). Moreover, whereas the management for diabetes was good, less than one-third of the patients with high blood pressure or dyslipidemia were treated for these conditions. Multivariate analysis showed that individuals with abnormal plasma c-reactive protein levels had a 3-fold increased risk (95% CI, 1.5-5.2) of having MetS, independent of other potential confounders.

Conclusion: The prevalence of MetS is higher in patients with TRD than in those with other psychiatric disorders and characterized by a considerable undertreatment of some components of MetS in this population. Diagnosis and treatment of the components of MetS should be systematically performed to prevent the occurrence of cardiovascular diseases in patients with TRD. These findings highlight the need for integrated care, with more interaction and coordination between psychiatrists and primary care providers.

Volume: 80

Quick Links:

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF